The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial

Procollagen type I C‐terminal propeptide (PICP) and procollagen type III N‐terminal propeptide (PIIINP) are markers reflecting collagen synthesis in cardiac fibrosis. However, they may be influenced by the presence of non‐cardiac comorbidities (e.g. ageing, obesity, renal impairment). Understanding the associations between markers of collagen synthesis and abnormalities of cardiac structure and function is important to screen for myocardial fibrosis and monitor the antifibrotic effect of medications.

[1]  S. Heymans,et al.  Biomarker‐based assessment of collagen cross‐linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial , 2021, European journal of heart failure.

[2]  P. Nilsson,et al.  Machine Learning-Derived Echocardiographic Phenotypes Predict Heart Failure Incidence in Asymptomatic Individuals. , 2021, JACC. Cardiovascular imaging.

[3]  J. Cleland,et al.  A novel treatment for heart failure targets myocardial fibrosis , 2021, Nature Medicine.

[4]  S. Heymans,et al.  The combination of carboxy‐terminal propeptide of procollagen type I blood levels and late gadolinium enhancement at cardiac magnetic resonance provides additional prognostic information in idiopathic dilated cardiomyopathy – A multilevel assessment of myocardial fibrosis in dilated cardiomyopathy , 2021, European Journal of Heart Failure.

[5]  Arantxa González,et al.  Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches , 2021, Nature Reviews Cardiology.

[6]  Arantxa González,et al.  Heart failure in chronic kidney disease: the emerging role of myocardial fibrosis. , 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[7]  S. Heymans,et al.  The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart ‘OMics’ in AGEing (HOMAGE) randomized clinical trial , 2020, European heart journal.

[8]  J. Cleland,et al.  Structural heart disease, cardiac dysfunction and heart failure: the ambiguity of a definition. , 2020, European journal of preventive cardiology.

[9]  E. Boerwinkle,et al.  Levels and Change in Galectin‐3 and Association With Cardiovascular Events: The ARIC Study , 2020, Journal of the American Heart Association.

[10]  J. Kovacic,et al.  Myocardial Interstitial Fibrosis in Nonischemic Heart Disease, Part 3/4: JACC Focus Seminar. , 2020, Journal of the American College of Cardiology.

[11]  S. Heymans,et al.  Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof‐of‐concept, randomised, precision‐medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial , 2020, European journal of heart failure.

[12]  Sanjiv J. Shah,et al.  Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF. , 2019, Journal of the American College of Cardiology.

[13]  D. Hulmes.  Roles of the procollagen C-propeptides in health and disease. , 2019, Essays in biochemistry.

[14]  F. Zannad,et al.  Is Sacubitril/Valsartan Antifibrotic? , 2019, Journal of the American College of Cardiology.

[15]  F. Tacke,et al.  Organ and tissue fibrosis: Molecular signals, cellular mechanisms and translational implications. , 2019, Molecular aspects of medicine.

[16]  A. Dominiczak,et al.  Biomarker‐based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo‐DHF trial , 2018, European journal of heart failure.

[17]  N. Sattar,et al.  Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure , 2018, Heart.

[18]  S. Solomon,et al.  Contemporary Assessment of Left Ventricular Diastolic Function in Older Adults: The Atherosclerosis Risk in Communities Study. , 2017, Circulation.

[19]  Patrizio Lancellotti,et al.  Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2016, European heart journal cardiovascular Imaging.

[20]  S. Solomon,et al.  Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study. , 2016, Circulation. Heart failure.

[21]  F. Zannad,et al.  Galectin-3 Blockade Inhibits Cardiac Inflammation and Fibrosis in Experimental Hyperaldosteronism and Hypertension , 2015, Hypertension.

[22]  Arantxa González,et al.  Circulating Biomarkers of Myocardial Fibrosis: The Need for a Reappraisal. , 2015, Journal of the American College of Cardiology.

[23]  F. Zannad,et al.  Reproducibility in Echocardiographic Assessment of Diastolic Function in a Population Based Study (The STANISLAS Cohort Study) , 2015, PloS one.

[24]  Don C Rockey,et al.  Fibrosis--a common pathway to organ injury and failure. , 2015, The New England journal of medicine.

[25]  Victor Mor-Avi,et al.  Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2015, European heart journal cardiovascular Imaging.

[26]  F. Zannad,et al.  The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries. , 2015, JACC. Heart failure.

[27]  F. Zannad,et al.  Features of Cardiac Remodeling, Associated With Blood Pressure and Fibrosis Biomarkers, Are Frequent in Subjects With Abdominal Obesity , 2014, Hypertension.

[28]  S. Solomon,et al.  GUIDELINES AND STANDARDS , 2010 .

[29]  W. Tang,et al.  Cardiorenal Syndrome Revisited , 2013 .

[30]  D. Levy,et al.  Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. , 2012, Journal of the American College of Cardiology.

[31]  D. Jędrzejuk,et al.  Left Ventricular Function Impairment in Patients With Normal-Weight Obesity: Contribution of Abdominal Fat Deposition, Profibrotic State, Reduced Insulin Sensitivity, and Proinflammatory Activation , 2012, Circulation. Cardiovascular imaging.

[32]  J. Cleland,et al.  Association of galectin‐3 and fibrosis markers with long‐term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE‐HF (Cardiac Resynchronization in Heart Failure) trial , 2012, European journal of heart failure.

[33]  M. Picard,et al.  Galectin‐3, cardiac structure and function, and long‐term mortality in patients with acutely decompensated heart failure , 2010, European journal of heart failure.

[34]  Arantxa González,et al.  Circulating Biomarkers of Collagen Metabolism in Cardiac Diseases , 2010, Circulation.

[35]  Tom Greene,et al.  Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate , 2006, Annals of Internal Medicine.

[36]  Arantxa González,et al.  Increased Collagen Type I Synthesis in Patients With Heart Failure of Hypertensive Origin: Relation to Myocardial Fibrosis , 2004, Circulation.

[37]  Arantxa González,et al.  Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. , 2004, Journal of the American College of Cardiology.

[38]  Arantxa González,et al.  Usefulness of Serum Carboxy-Terminal Propeptide of Procollagen Type I in Assessment of the Cardioreparative Ability of Antihypertensive Treatment in Hypertensive Patients , 2001, Circulation.

[39]  F. Alla,et al.  Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure: Insights From the Randomized Aldactone Evaluation Study (RALES) , 2000, Circulation.

[40]  J. Emparanza,et al.  Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. , 2000, Circulation.

[41]  C. Brown,et al.  Urinary and serum type III collagen: markers of renal fibrosis. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[42]  Herman Aguinis,et al.  Statistical Power with Moderated Multiple Regression in Management Research , 1995 .

[43]  K. Weber,et al.  Cardiac interstitium in health and disease: the fibrillar collagen network. , 1989, Journal of the American College of Cardiology.